A Study of Itraconazole in the Prevention of Histoplasmosis, a Fungal Infection, in HIV-Infected Patients

Inclusion Criteria Patients must have: * HIV infection. * Residence in an area endemic for H. capsulatum. * Absolute CD4 count \< 150 cells/mm3. * No current or past active histoplasmosis. * No other active fungal infection. * Life expectancy of at least 1 year. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: * Life-threatening infection or malignancy other than cutaneous Kaposi's sarcoma. * Inability to take oral medication. Concurrent Medication: Excluded: * Systemically-active antifungals. * Investigational drugs (expanded access drugs are acceptable). * Rifampin. * Rifabutin. * Terfenadine. * Astemizole. * Phenobarbital. * Phenytoin. * Carbamazepine. * H2 blockers. * Omeprazole. * Continual antacids. Patients with the following prior conditions are excluded: History of intolerance to imidazole or azole compounds. Prior Medication: Excluded within 1 month prior to study entry: * Investigational drugs (expanded access drugs are acceptable). Excluded within 15 days prior to study entry: * Rifampin. * Rifabutin. * Terfenadine. * Astemizole. * Phenobarbital. * Phenytoin. * Carbamazepine.